Delamanid
- Generic Name
- Delamanid
- Brand Names
- Deltyba
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25F3N4O6
- CAS Number
- 681492-22-8
- Unique Ingredient Identifier
- 8OOT6M1PC7
- Background
Delamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall . It is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a combination regimen. Emergence of multidrug-resistant and extensively drug-resistant tub...
- Indication
Indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability .
- Associated Conditions
- Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
- Associated Therapies
- -
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06649721
- Locations
- 🇨🇳
Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳Beijing Tsinghua Changgun Hospital, Beijing, Beijing, China
🇨🇳The 8th Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China
Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT06224036
- Locations
- 🇨🇳
Wuhan Chest Hospital (Wuhan Institute For Tuberculosis Control), Wuhan, Hubei, China
🇨🇳West China Hospital, Sichuan University, Chendu, Sichuan, China
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT06081361
- Locations
- 🇨🇳
The 8th Medical Center of Chinese Pla General Hospital, Beijing, China
🇨🇳Hebei Chest Hospital, Shijiazhuang, Hebei, China
🇨🇳Harbin Chest Hospital, Harbin, Heilongjiang, China
BTZ-043 Dose Evaluation in Combination and Selection
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 90
- Registration Number
- NCT05926466
- Locations
- 🇹🇿
National Institute for Medical Research (NIMR-Mwanza),, Mwanza, Tanzania
🇿🇦TASK Applied Sciences Clinical Research Centre, Cape Town, South Africa
🇹🇿National Institute for Medical Research (NIMR-MMRC), Mbeya, Tanzania
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 288
- Registration Number
- NCT05766267
- Locations
- 🇺🇸
TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States
🇺🇸TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States
🇺🇸TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 156
- Registration Number
- NCT05556746
- Locations
- 🇭🇹
GHESKIO, Port-au-Prince, Haiti
🇿🇦University of Cape Town, Cape Town, South Africa
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 128
- Registration Number
- NCT05382312
- Locations
- 🇿🇦
GSK Investigational Site, Cape Town, South Africa
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 608
- Registration Number
- NCT04421495
- Locations
- 🇨🇳
Public Health Clinical Center of Chengdu, Chengdu, China
🇨🇳Heilongjiang Province center for tuberculosis Control and Prevention, Haerbin, China
🇨🇳Tuberculosis Hospital in Jilin Province, Jilin, China
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Boston University
- Target Recruit Count
- 220
- Registration Number
- NCT03828201
- Locations
- 🇻🇳
National Lung Hospital, Hanoi, Vietnam
🇵🇭De La Salle Health Sciences Institute, Dasmariñas, Philippines
Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB
- Conditions
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 37
- Registration Number
- NCT03141060
- Locations
- 🇮🇳
Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India
🇿🇦Sizwe CRS, Johannesburg, Gauteng, South Africa
🇿🇦PHRU Matlosana CRS, Klerksdorp, North West Province, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.